

## Epivir - Lamivudine 300mg tablets

### Prescribing Information

See Summary of Product Characteristics (SmPC) before prescribing

**Indications:** HIV in adults, adolescents and children weighing at least 25 kg as part of combination therapy. **Dose:** Adults: one 300mg tablet daily with or without food. See SmPC for dosage in children and adolescents. Additional formulations available: 150mg tablets and Oral Solution (10mg/mL) – see SmPCs. **Elderly:** No specific data. **Renal impairment:** Creatinine clearance <50ml/min: see SmPC for dosage adjustment. **Hepatic impairment:** no dose adjustment required. **Contraindications:** Hypersensitivity to any ingredient. **Special warnings/precautions:** High risk of virological failure (when used in a triple nucleoside regimen), immune reactivation syndrome, osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C co-infection. Use with cladribine,

emtricitabine or high doses of co-trimoxazole not recommended. When possible, avoid chronic co-administration of sorbitol or other osmotic acting alcohols (see SmPC section 4.5). If unavoidable, consider more frequent viral load monitoring.

**Pregnancy/lactation:** Not recommended. Do not breast-feed. **Side effects:** See SmPC for full details. Headache, GI disturbance, insomnia, cough, nasal symptoms, rash, alopecia, arthralgia, muscle disorders, fatigue, malaise, fever, blood dyscrasias, pancreatitis, hepatitis, angioedema, rhabdomyolysis, lactic acidosis, peripheral neuropathy. Transient increases in liver enzymes. **Basic NHS costs:** 30 tablets £157.51. **MA number:** EU/1/96/015/003.

**MA holder:** ViiV Healthcare BV,  
Van Asch van Wijckstraat 55H,  
3811 LP Amersfoort , Netherlands.  
Further information available from:  
[customercontactuk@gsk.com](mailto:customercontactuk@gsk.com)  
Freephone 0800 221 441.

POM

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

Date of approval: May 2020

PI-0481v2

Adverse events should be reported. For the UK, reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for **MHRA Yellowcard** in the **Google Play or Apple App store**. Adverse events should also be reported to GSK on 0800 221441.